Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of an experimental drug called PTX-022, which is a topical gel containing 3.9% sirolimus, for treating angiokeratomas. This Phase 2 study aims to understand how well PTX-022 works and its safety profile in patients with this condition. The study is sponsored by Palvella Therapeutics, Inc. and includes participants aged 6 years and older. Participants in this open-label study will receive PTX-022 applied topically. The treatment period lasts for 3 months during which the drugs effects and safety will be monitored. There are no placebo or comparator groups all participants receive the experimental treatment. During the study, participants will be assessed for any treatment-related side effects and changes in their angiokeratomas using the Investigator Global Assessment and Patient Global Impression of Change scales. Researchers will collect data on adverse events and overall improvement at the 3-month mark. Participants are expected to follow all study procedures, including medication application and scheduled evaluations throughout the study duration.
Actively Recruiting
Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.
Actively Recruiting
Researchers are evaluating the effectiveness and long-term safety of PP405, a medicated topical gel, for treating Androgenetic Alopecia in adult males aged 18 to 55. This phase 23 randomized, double-blind study involves men who have experienced hair loss for at least six months and have specific severity scores on the Norwood-Hamilton scale. Participants are randomly assigned to receive either PP405 topical gel or a non-medicated vehicle gel applied to the scalp once daily for 24 weeks. After this initial period, those on PP405 continue the treatment while participants initially on the vehicle are re-randomized to either PP405 or vehicle for an additional 28 weeks, creating a total treatment duration of 52 weeks to assess both efficacy and safety over time. Throughout the study, participants will be regularly assessed for changes in hair count and scalp coverage using both clinical and participant evaluations at weeks 12 and 24. Safety monitoring continues during the extension phase up to week 52. The primary outcome focuses on the change in non-vellus target area hair count at week 24, with secondary measures including participant assessments of scalp coverage and hair count improvements at weeks 12 and 24.